Three Abstracts on the ChemoFx(R) Drug Response Marker Accepted by ASCO - MarketWatch

Three Abstracts on the ChemoFx(R) Drug Response Marker Accepted by ASCO - MarketWatch

".....The third abstract titled, In Vitro Chemoresponse Assay Results and Population Clinical Response Rates in Women with Ovarian Cancer, determines whether in vitro platinum sensitivity rates are similar to published population response rates for ovarian cancer and examines differences in platinum sensitivity across histologic subtypes."

"We are very pleased with the outcomes to date from these three studies," says Dr. Karl Williams, Chief Medical Director for Precision Therapeutics, Inc. "We look forward to watching these projects progress and further analyzing the value of ChemoFx for these difficult to treat patients." 

For more information, visit: www.precisiontherapeutics.com or www.chemofx.com .

SOURCE: Precision Therapeutics Inc.

Chemoresponse Assay Could Lower Treatment Costs in Ovarian Cancer - ChemoFx

 "...In the study, the authors assumed, for the sake of analysis, that the "outcomes are likely no worse when chemoresponse testing is performed than when an empiric choice of regimen is made."
However, if, in currently ongoing studies, the assay helps clinicians choose more effective therapies and thus improve survival, it would be "very attractive from a health economics perspective," say the authors, because the current study has already shown it to be cost effective."
 
The study was funded by Precision Therapeutics.